Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
May 5, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3426011 3816393 Inclusion compound of lankacidin-group antibiotic and use thereof Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof Inclusion complex of ଲ-cyclodextrin and digoxin Water-soluble mixed ethers of ଲ-cyclodextrin and a process for their preparation Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives Ethers of beta-cyclodextrin and a process for their preparation Pharmaceutical preparations containing cyclodextrin derivatives Partially methylated cyclodextrins and process for producing the same InventorsAssigneeApplicationNo. 851006 filed on 05/05/1997US Classes:514/58, Dextrin or derivative514/778, Starch or derivative514/964, SUSTAINED OR DIFFERENTIAL RELEASE TYPE514/965, Discrete particles in supporting matrix536/103Dextrin or derivativeExaminersPrimary: Kunz, Gary L.Attorney, Agent or FirmInternational ClassesA61K 031/735C07H 013/12 C08B 037/16 AbstractSulfoalkyl ether-cyclodextrin (SAE-CD) based pharmaceutical formulations are provided by the present invention. These formulations comprise SAE-CD derivatives and a therapeutic agent, a major portion of which is not complexed to the SAE-CD. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative can be used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents.Other References
|
| ||||||||||||||
